Preoperative Lenvatinib Plus Pembrolizumab in Early-Stage Triple-Negative Breast Cancer (TNBC)
Status:
Recruiting
Trial end date:
2026-07-01
Target enrollment:
Participant gender:
Summary
This is a single arm, window of opportunity study in which participants with previously
untreated triple negative breast cancers (TNBC) who are candidates for potentially curative
surgery will receive one 21-day cycle of therapy prior to surgery, consisting of lenvatinib
12 mg daily, days 1 through 14, and pembrolizumab 200 mg IV on day 1